FDA
Hydralazine Hydrochloride
The FDA lists this product in 60 strengths and forms.
Indications
Essential hypertension, alone or as an adjunct.
Contraindications
Hypersensitivity to hydrALAZINE; coronary artery disease; mitral valvular rheumatic heart disease.
Warnings and precautions
In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary.
(See PRECAUTIONS , Laboratory Tests . )
Interactions
Drug/Drug Interactions: MAO inhibitors should be used with caution in patients receiving hydrALAZINE. When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydrALAZINE, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide injection and hydrALAZINE are used concomitantly.
Pregnancy and breastfeeding
Pregnancy Category C: Animal studies indicate that hydrALAZINE is teratogenic in mice at 20 to 30 times the maximum daily human dose of 200 to 300 mg and possibly in rabbits at 10 to 15 times the maximum daily human dose, but that it is nonteratogenic in rats. Teratogenic effects observed were cleft palate and malformations of facial and cranial bones. There are no adequate and well-controlled studies in pregnant women.
Although clinical experience does not include any positive evidence of adverse effects on the human fetus, hydrALAZINE should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.
Adverse reactions
Adverse reactions with hydrALAZINE are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug. The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency. Common: Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris Less Frequent: Digestive: constipation, paralytic ileus.
At a glance
- Brand name
- Hydralazine Hydrochloride
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Hetero Labs LTD III
- Status
- Prescription
- FDA approval
- 12 Sept 2008
- Application
- ANDA040901-001



